By Denny Jacob
Dyne Therapeutics shares slide 7.3% to $13.69 in post-market trading after it said it commenced an underwritten public offering of $175 million of shares of its common stock.
The stock, which closed up 13% to $14.77, is up 25% over the last 12 months.
The clinical stage muscle disease company said it also intends to grant the underwriters a 30-day option to purchase up to an additional $26.3 million of shares of its common stock. All of the shares in the proposed offering are being sold by Dyne.
Write to Denny Jacob at [email protected]
Read the full article here
